Opinion|Videos|February 27, 2025
Lessons from TiNivo-2 and CONTACT-03
Author(s)Sumanta Kumar Pal, MD
A panelist discusses how the CONTACT-03 and TiNivo-2 studies yielded important insights about ICI rechallenge and tivozanib in the post-ICI setting, with particular attention to the notable 9.2-month median PFS with tivozanib monotherapy, the impact of dosing strategies, and the timing of therapy initiation, though questions remain about the broader implications for ICI rechallenge efficacy across different treatment contexts.
Episodes in this series
Video content above is prompted by the following:
- What was learned from the CONTACT-03 and TiNivo-2 studies?
- What is your reaction to the efficacy data
- The combination arm?
- The tivozanib monotherapy arm?
- The 9.2-month median PFS of second-line tivo immediately following an ICI?
- Do you consider the results to be meaningful or practice changing?
- Please discuss the reduced dosage of tivozanib used in TiNivo-2 and the inclusion of patients with a ≤6 week break from immediate prior therapy in TiNivo-2?
- Please contrast that w/ design of CONTACT-03
- Do you agree that the results of the TiNivo-2 and CONTACT-03 studies clearly demonstrate that ICI rechallenge is not efficacious?
Related Content
Advertisement
